

SPARC/Sec/SE/2019-20/043

18th November 2019

To
BSE Limited
P J Towers,
Dalal street,
Mumbai - 400001

National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai – 400 051.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Sub: Disclosure of Related Party Transactions – September 2019

Dear Sir/ Madam,

In compliance with Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendments) Regulations, 2018, we hereby submit the Related Party Transactions on consolidated basis, in accordance with the applicable accounting standards, for the half year ended September 30, 2019.

This is for your information and record.

Thanking you,
Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

A handwritten signature in black ink, appearing to read "Debashis Dey".

Debashis Dey
Company Secretary

Encl: As above.

Indian Accounting Standard (Ind AS-24) " Related Party Disclosures "

Names of related parties and description of relationship

1. Key Management Personnel

Dilip S. Shanghvi	Chairman & Managing Director
Sudhir V. Valia	Non Executive Director
Rajamannar Tennati	Non-Executive Director
Bhavna Doshi	Independent Director
Ferzaan Engineer	Independent Director
Mark J. Simon	Independent Director

2. Holding Company

Shanghvi Finance Private Limited

3. Enterprise under Significant Influence of Key Management Personnel (with whom transactions are entered)

Alkaloida Chemical Company ZRT	Sun Pharmaceutical Industries Inc.
Sun Pharma Global FZE	Sun Pharmaceutical Industries Limited
Sun Pharma Laboratories Limited	Sun Pharmaceutical Medicare Limited
Sun Pharmaceutical Industries Europe BV	Taro Pharmaceuticals Industries Limited

₹ In Lakhs

Particulars	Half Year ended Sep 30, 2019
Alkaloida Chemical Company ZRT	
Purchase of goods	4.56
Mark J. Simon	
Receiving of research and development services	35.78
Sun Pharma Global FZE	
Sale of services - License fees / Royalty on technology / R&D services	307.85
Sun Pharma Laboratories Limited	
Sale of services - License fees / Royalty on technology / R&D services	1,720.12
Purchase of Goods	1.21
Sun Pharmaceutical Industries Europe BV	
Purchase of goods	6.25
Sun Pharmaceutical Industries Inc.	
Sale of services - License fees / Royalty on technology / R&D services	1.38
Reimbursement / Receiving of research and development services	3,091.43
Purchase of goods	140.01
Sun Pharmaceutical Industries Limited	
Sale of services - License fees / Royalty on technology / R&D services	1,420.19
Purchase of goods (Net)	7.12
Purchase of fixed assets	2.85
Rent expense	101.47
Receiving of research and development services	133.30
Reimbursement of expenses paid	222.62
Reimbursement of expenses received	0.86




Particulars	Half Year ended Sep 30, 2019
Sun Pharmaceutical Medicare Limited	
Sale of Goods	7.15
Purchase of fixed assets	0.15
Purchase of Goods	1.00
Taro Pharmaceuticals Industries Limited	
Sale of services - R&D services	1.89
Receiving of research and development services	23.06
Director Sitting Fees	
Sudhir V. Valia	1.20
Bhavna Doshi	3.00
Rajamannar Tennati	1.50
Ferzaan Engineer	3.00
Mark Simon	3.00

Balance outstanding - Receivable / (Payable)

Particulars	As at Sep 30, 2019
Sun Pharma Global FZE	244.03
Sun Pharma Laboratories Limited	900.30
Sun Pharmaceutical Industries Europe BV	(55.86)
Sun Pharmaceutical Industries Inc.	(5,745.60)
Sun Pharmaceutical Industries Limited	613.07
Sun Pharmaceutical Medicare Limited	6.40
Taro Pharmaceuticals Industries Limited	(20.79)

Terms and condition of transaction with related parties.

The sale of services to related parties are made on terms equivalent to those that prevail in arms length transactions. Outstanding balances as on 30th September 2019 are unsecured and interest free and settlement occurs in cash. There have been no guarantees provided or received for any related parties receivables or payable.



Chetan M. Rajpara
Chief Financial Officer

